Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Bolsa de Madrid  >  Almirall, S.A.    ALM   ES0157097017

ALMIRALL, S.A.

(ALM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Almirall : Exercises its Option with Dermira to License Rights to Lebrikizumab in Europe for Atopic Dermatitis

share with twitter share with LinkedIn share with facebook
share via e-mail
06/26/2019 | 07:16am EST

Almirall, S.A. (BME: ALM) and Dermira, Inc. (NASDAQ: DERM) announced today that Almirall has exercised its option to license rights to develop and commercialize lebrikizumab for the treatment of atopic dermatitis and certain other indications in Europe. Almirall and Dermira previously entered into an option and license agreement in February 2019 pursuant to which Almirall was granted this exclusive option in exchange for an upfront option fee of $30 million. As a result of Almiralls decision to exercise its option, the company will pay Dermira$50 million, and Dermira will be eligible to receive additional payments upon the achievement of certain milestones, including $30 million in connection with the initiation of certain Phase 3 clinical studies.

Almiralls decision follows positive topline results reported by Dermira in March 2019 from a Phase 2b dose-ranging study that showed all three doses of lebrikizumab met the primary endpoint, and demonstrated dose-dependent improvements across a range of measures characterizing the signs and symptoms of moderate-to-severe atopic dermatitis, including itch and skin inflammation, compared to placebo. The safety profile observed in the study was consistent with prior studies of lebrikizumab. The findings suggest that lebrikizumab has the potential to be a best-in-disease therapy for people living with moderate-to-severe atopic dermatitis. Following an end-of-Phase 2 meeting with the U.S. Food and Drug Administration, Dermira plans to initiate a Phase 3 clinical development program for lebrikizumab by the end of 2019.

We are incredibly pleased to collaborate with Dermira on the lebrikizumab clinical development program and excited by the prospect of delivering what could be a best-in-disease therapy for people living with moderate-to-severe atopic dermatitis in Europe, which Almirall believes could achieve potential peak sales of around 450 million euros, said Peter Guenter, chief executive officer of Almirall. This transaction reinforces our shared commitment to the dermatology community and supports our vision of offering truly meaningful, new treatment advances to people living with chronic, life-altering skin conditions.

Lebrikizumab is a novel, injectable, humanized monoclonal antibody designed to bind interleukin-13 (IL-13) with very high affinity, specifically preventing the formation of the IL-13R1/IL-4R heterodimer complex and subsequent signaling, thereby inhibiting the biological effects of IL-13 in a targeted and efficient fashion. IL-13 is believed to be a central pathogenic mediator that drives multiple aspects of the pathophysiology of atopic dermatitis by promoting type 2 inflammation and mediating its effects on tissue, resulting in skin barrier dysfunction, itch, skin thickening and infection.

Under the terms of the option and license agreement entered into between Almirall and Dermira in February 2019, Almirall paid Dermira an upfront option fee of $30 million in exchange for an option to acquire an exclusive license to develop lebrikizumab in dermatology indications and commercialize lebrikizumab in all indications in Europe. As a result of its decision to exercise its option, Almirall will pay Dermira an option exercise fee of $50 million. In addition, Almirall will make additional payments to Dermira upon the achievement of certain milestones, including $30 million in connection with the initiation of certain Phase 3 clinical studies and up to $85 million upon the achievement of regulatory milestones and the first commercial sale of lebrikizumab in Europe. Dermira will also be entitled to receive milestone payments upon the achievement of certain thresholds for net sales of lebrikizumab in Europe, as well as royalty payments representing percentages of net sales that range from the low double-digits to the low twenties.

The unique characteristics of lebrikizumab and positive findings observed in our Phase 2b dose-ranging study suggest that we have the potential to offer people living with moderate-to-severe atopic dermatitis, and the healthcare practitioners who care for them, a differentiated treatment option that delivers a compelling combination of safety, efficacy, tolerability, convenience and ease of use, said Tom Wiggans, chairman and chief executive officer of Dermira. As we look to initiate our Phase 3 program by the end of this year, Dermira is pleased to partner with Almirall to potentially bring this exciting new treatment option to patients in Europe, while we continue to pursue development and potential commercialization in the United States.

(c) 2003-2019 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Stocks mentioned in the article
ChangeLast1st jan.
ALMIRALL, S.A. -2.19% 12.08 End-of-day quote.-17.49%
DERMIRA, INC. 0.00%End-of-day quote.23.68%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ALMIRALL, S.A.
02/24GLOBAL MARKETS LIVE: The market purge weighs more heavily on a few sectors
02/24ALMIRALL S A : Full-Year 2019 Results Strong operational performance with excell..
PU
02/24ALMIRALL S A : Spain's Almirall reports 2019 profit hike
RE
02/24ALMIRALL S A : and Paratek enter into a License Agreement for Seysara® in China
PU
02/19ALMIRALL, S.A. : annual earnings release
02/06ALMIRALL S A : partners with Plug and Play to accelerate digital innovation in d..
PU
01/15ALMIRALL S A : to participate in J.P. Morgan Healthcare Conference in San Franci..
PU
01/09ALMIRALL S A : signs a strategic agreement with 23andMe to license rights of a b..
PU
01/09ALMIRALL S A : and WuXi Biologics sign strategic collaboration agreement for mul..
PU
01/08ALMIRALL S A : enters into an option agreement to acquire Bioniz Therapeutics an..
PU
More news
Financials (EUR)
Sales 2020 890 M
EBIT 2020 165 M
Net income 2020 96,0 M
Debt 2020 270 M
Yield 2020 1,57%
P/E ratio 2020 21,5x
P/E ratio 2021 15,4x
EV / Sales2020 2,67x
EV / Sales2021 2,29x
Capitalization 2 109 M
Chart ALMIRALL, S.A.
Duration : Period :
Almirall, S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALMIRALL, S.A.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 18,55  €
Last Close Price 12,08  €
Spread / Highest target 65,6%
Spread / Average Target 53,6%
Spread / Lowest Target 15,9%
EPS Revisions
Managers
NameTitle
Peter Guenter Chief Executive Officer & Director
Jorge Gallardo Ballart Chairman
Michael McClellan Chief Financial Officer
Eloi Crespo Cervera Vice President-Manufacturing & Technical Services
Bhushan D. Hardas Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALMIRALL, S.A.-17.49%2 294
JOHNSON & JOHNSON2.78%384 432
ROCHE HOLDING AG10.13%290 942
NOVARTIS2.72%211 608
MERCK AND COMPANY-10.58%207 065
PFIZER-8.83%191 868